Kalypsys has multiple, structurally diverse, preclinical stage candidates which are positioned as development backups to KD5170.
Preclinical and clinical data demonstrate that small molecule kinase inhibitors are increasingly important as novel molecular therapeutics for cancer. Kalypsys is pursuing broad-spectrum kinase inhibitors that target B-Raf and additional kinases that stimulate tumor-associated angiogenesis. Preclinical stage compounds that demonstrate anti-tumor activity in murine xenograft models have been identified.
The B-Raf gene is commonly mutated to oncogenic forms in up to 70% of malignant melanomas, and lower percentages in several other prevalent human cancers. Animal models utilizing human melanoma tumor cells demonstrate anti-tumor efficacy by selective inhibition of B-Raf. Kalypsys is pursuing selective B-Raf inhibitors targeting tumor types with frequent B-Raf mutations. Multiple chemical series are presently being evaluated in vivo preclinical studies.
